Multi-species toxicology approaches for oncology drugs
- 1 April 2004
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 40 (6) , 907-913
- https://doi.org/10.1016/j.ejca.2003.11.024
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Toxicity testing in the development of anticancer drugsThe Lancet Oncology, 2002
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Prospects for reducing and refining the use of dogs in the regulatory toxicity testing of pharmaceuticalsHuman & Experimental Toxicology, 2000
- Concordance of the Toxicity of Pharmaceuticals in Humans and in AnimalsRegulatory Toxicology and Pharmacology, 2000
- Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced CancerJournal of Clinical Oncology, 2000
- Regulatory considerations for preclinical development of anticancer drugsCancer Chemotherapy and Pharmacology, 1997
- Managing the drug discovery/development interfaceDrug Discovery Today, 1997
- Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in EuropeEuropean Journal Of Cancer, 1995
- The Use of the Dog in Toxicity Tests on Pharmaceutical CompoundsHuman & Experimental Toxicology, 1993